Remdesivir, an adenosine triphosphate analogue initially investigated as a potential treatment for Ebola, has been extensively profiled for its broad-spectrum antiviral activity against multiple RNA viruses, according to research published in Scientific Reports in February 2023.
The drug functions as a prodrug, meaning it is metabolized within the body to form its active component, GS-443902, also known as remdesivir-triphosphate. This active metabolite acts as a delayed chain terminator, inhibiting viral RNA-dependent RNA polymerases – a crucial step in viral replication. The research detailed in Scientific Reports, conducted by scientists at the U.S. Army Medical Research Institute of Infectious Diseases, Gilead Sciences, and multiple international institutions, including KU Leuven in Belgium, examined Remdesivir’s potential for low interaction with other medications.
Remdesivir was designed to target RNA viruses, including hepatitis C, and has demonstrated in vitro activity against viruses belonging to the Arenaviridae, Flaviviridae, Filoviridae, and Paramyxoviridae families, as noted by DrugBank. The prodrug is bioactivated in the body, functioning as an adenosine triphosphate (ATP) analogue. According to ScienceDirect Topics, a suggested administration model involves a single dose on the first day, followed by two additional doses on subsequent days.
The active nucleotide, GS-443902, is structurally similar to 1′-cyano-substituted ATP, differing only in the substitution of adenosine’s purine base, as detailed in a study published in The Lancet. This structural similarity allows it to interfere with the viral replication process. The study in The Lancet emphasizes the importance of early administration for antiviral treatments, a characteristic relevant to Remdesivir’s mechanism of action.
The research published in Scientific Reports involved Sheli R. Radoshitzky of The Geneva Foundation and the U.S. Army Medical Research Institute of Infectious Diseases, alongside contributions from Patrick Iversen, Xianghan Lu of Gilead Sciences, Jing Zou of the University of Texas Medical Branch, Suzanne J.F. Kaptein of KU Leuven and the Global Virus Network, Kelly S. Stuthman, and Sean A. Van Tongeren, among others. The study’s findings contribute to a growing body of evidence supporting Remdesivir’s potential as a broad-spectrum antiviral agent.
